Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Chief Commercial Officer | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option, right to buySEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2028-03-02 | Direct | 165,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 165,000 · Balance 165,000 F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 22, 2018 15:24 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option, right to buy · Derivative | 165,000 | $5.65 Strike: $5.65 | $932,250.00 |
DisclosureSEC source: 0001288123-18-000008 · primary_doc.xml · derivative · entry 1 Baysal Ozer · CIK 0001579446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2028-03-02 F1 · derivative.exercise_date: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:38 UTC | AGENUS INC AGEN · Entity 5774 | SaleCommon Stock | 3,712 | $3.46 | $12,845.75 |
DisclosureSEC source: 0001288123-17-000044 · primary_doc.xml · nonDerivative · entry 2 Baysal Ozer · CIK 0001579446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,790 F2 · kind: Represents sales of shares sold solely to cover Federal, state and local tax withholding requirements on the restricted shares settled and were sold at prices ranging between $3.49 and $3.44 per share. F2 · price: Represents sales of shares sold solely to cover Federal, state and local tax withholding requirements on the restricted shares settled and were sold at prices ranging between $3.49 and $3.44 per share. Read SEC document |
| October 09, 2017 Filed Dec 14, 2017 21:38 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 13,080 | $3.59 | $46,957.20 |
DisclosureSEC source: 0001288123-17-000044 · primary_doc.xml · nonDerivative · entry 1 Baysal Ozer · CIK 0001579446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,502 F1 · kind: Represents settlement of restricted shares awarded on July 1, 2015. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:23 UTC | AGENUS INC AGEN · Entity 5774 | Disposition to issuerCommon Stock | 3,539 | $3.39 | $11,997.21 |
DisclosureSEC source: 0001288123-17-000023 · primary_doc.xml · nonDerivative · entry 2 Baysal Ozer · CIK 0001579446 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,422 F2 · kind: Represents exclusively, shares withheld by Agenus Inc. in respect of payment of the withholding tax liability upon the vesting of the restricted shares. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:23 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 13,078 | $3.39 | $44,334.42 |
DisclosureSEC source: 0001288123-17-000023 · primary_doc.xml · nonDerivative · entry 1 Baysal Ozer · CIK 0001579446 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,961 F1 · kind: Represents settlement of vested restricted shares granted on July 1, 2015. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:39 UTC | AGENUS INC agen · Entity 5774 | GrantStock Option, Right to Buy · Derivative | 75,000 | $3.77 Strike: $3.77 | $282,750.00 |
DisclosureSEC source: 0001288123-17-000012 · primary_doc.xml · derivative · entry 1 Baysal Ozer · CIK 0001579446 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-31 F1 · derivative.exercise_date: Options vest one-third on the one-year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 01:39 UTC | AGENUS INC agen · Entity 5774 | GrantCommon Stock | 6,250 | $4.16 | $26,000.00 |
DisclosureSEC source: 0001288123-17-000003 · primary_doc.xml · nonDerivative · entry 1 Baysal Ozer · CIK 0001579446 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,883 F1 · kind: Represents the settlement of restricted stock awarded on January 2, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.